Luton, Bedfordshire, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) — The global angioplasty market for peripheral arterial disease (PAD) is expanding steadily, driven by rising PAD prevalence and technological advances. In 2024 the worldwide peripheral angioplasty market was estimated at roughly USD 4.2 billion and is projected to nearly double by 2034 to about USD 9.0 billion (CAGR 8%). This reflects broader PAD treatment trends: industry analysis projects the overall PAD device market growing at ~7% annually. Key growth factors include aging populations, increasing diabetes/obesity, and a shift to minimally invasive procedures. Advanced endovascular devices (drug-eluting balloons and stents, reabsorbable scaffolds) are improving patient outcomes and expanding indications. Hospitals and specialized cardiac centers, which have the required cath-lab facilities, remain the dominant sites for angioplasty procedures. North America accounts for the largest share of PAD angioplasty spending (roughly 40–45%), thanks to high disease burden and strong healthcare infrastructure. Europe is the second‐largest market (led by Germany and the UK), while Asia–Pacific (especially China and India) is the fastest-growing region as awareness and access improve.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/54956/global-peripheral-artery-angioplasty-market#request-a-sample
Global PAD interventions attract intense competition: major device makers (Medtronic, Boston Scientific, Abbott, Cordis/Johnson & Johnson, Terumo, B. Braun, Biotronik, Cook, etc.) are continually launching new products and forging partnerships. Industry players report that balloon angioplasty catheters (especially drug-coated balloons, DCBs) form the largest single product segment (by revenue). Hospitals hold the lion’s share of procedures, though outpatient/ambulatory centers are expanding. Importantly, regulatory approvals and reimbursement policies strongly influence adoption: for example, the U.S. FDA’s 2023 review reaffirmed the safety of paclitaxel-coated devices, and new approvals (e.g. Abbott’s Esprit BTK stent) open up novel treatment options.
Market Dynamics and Drivers
- Rising PAD prevalence: PAD affects millions worldwide, especially elderly and diabetic patients. The increasing incidence of atherosclerosis drives demand for angioplasty interventions. For example, risk factors like diabetes and hypertension are fueling PAD rates, which in turn propels the need for revascularization procedures. Early PAD treatment campaigns and screening programs (notably in North America and Europe) also boost diagnosis and treatment.
- Minimally invasive preference: Clinicians favor angioplasty (balloon/stent) over open surgery due to shorter recovery and fewer complications. As one industry report notes, “Stakeholders who invest in R&D…stand to gain the most”, because new catheters and stents allow less-invasive management of chronic limb-threatening ischemia.
- Technological innovation: Advances such as drug-coated balloons (DCBs), drug-eluting stents (DES), and bioresorbable scaffolds are expanding indications and efficacy. Many next-generation devices (e.g. Abbott’s everolimus-eluting “dissolving” stent for below-the-knee arteries) have reached the market recently. Intravascular lithotripsy (IVL) systems and improved guidewire/crossing technologies are also being adopted for complex, calcified lesions. These innovations prolong vessel patency and reduce re-intervention rates, stimulating market growth.
- Regulatory support and reimbursement: Favorable reimbursement (especially in developed countries) encourages angioplasty use over drug therapy alone. Many governments and insurers have approved PAD interventions as standard of care. The recent FDA stance that paclitaxel-coated balloons and stents do not carry excess mortality risk has cleared a major regulatory hurdle, allowing continued use of these devices. In Europe, CE marking under the new MDR framework has tightened safety standards (for example, devices like AngioDynamics’ laser atherectomy system Auryon received CE Mark in 2024, highlighting regulatory momentum). Price pressures exist, but innovation (and the need for cost-effective chronic disease management) continues to draw investment.
- Shifting demographics: Aging populations in North America and Europe drive growth, as PAD is more common in older patients. Meanwhile, increasing healthcare spending and greater physician training in China and India are rapidly expanding Asia-Pacific demand. Governments in emerging markets are building PAD awareness campaigns and reimbursement frameworks, further enlarging the addressable market.
Market Segmentation
By Product Type
- Balloon Catheters: This category (including plain balloons and drug-coated balloons) is the largest segment. Balloon angioplasty is the core of PAD intervention, and most procedures begin with a percutaneous transluminal angioplasty (PTA) balloon. Drug-coated balloons (typically paclitaxel or sirolimus-eluting) are increasingly used to inhibit restenosis. Industry analysis indicates “the balloon catheters are expected to dominate the peripheral angioplasty industry” with continued steady growth. Balloons offer a cost-effective, minimally invasive option, which keeps their market share high (estimated well over 50% of revenue in devices).
- Stents: Traditional bare-metal stents and newer drug-eluting stents constitute the next-largest segment. Stents are often used after angioplasty to scaffold the artery, especially for flow-limiting dissections or recoil. The introduction of DES (e.g. Boston’s Eluvia, Abbott’s expanding pipeline, Biotronik’s devices) has lifted this segment’s growth. Resorbable scaffolds (Abbott Esprit BTK) and hybrid stents (drug-coated) are gaining traction. However, stent use is somewhat lower in peripheral arteries compared to coronary, since smaller vessels (below-knee) and long lesions are harder to scaffold. Still, stents represent a significant share (perhaps 25–30%) of the angioplasty devices market.
- Guidewires: Guidewires, catheters, and ancillary devices (e.g. sheaths, imaging catheter) form the remaining portion. These items are used in every intervention but individually lower-priced. The guidewires segment is the smallest by revenue (roughly 10–15%), but it is indispensable. Leading guidewire products (e.g. hydrophilic-coated wires by Terumo, etc.) continue to innovate for crossing CTOs and tortuous anatomy. Although guidewire sales grow more slowly, they are a stable base of the market.
By Application
- Peripheral Artery Disease (PAD): The vast majority of this market concerns PAD (femoropopliteal and below-knee arteries). Indeed, PAD interventions are driving the market growth described above. Peripheral angioplasty is used to treat stenoses and occlusions in leg arteries and, less often, renal or upper-extremity arteries. (By contrast, coronary angioplasty for heart disease is usually treated as a separate market; global coronary stent markets are much larger.) Within the PAD context, a high proportion of cases involve critical limb ischemia or severe claudication. Minimally invasive angioplasty (with or without stenting) is increasingly used to avoid amputations in these patients. Estimates suggest that angioplasty balloons alone account for over 40% of PAD device revenue, underscoring the dominance of PAD applications in this market.
- Coronary Artery Disease (CAD): Although coronary interventions (angioplasty for heart arteries) employ similar technologies, these are generally tracked separately. If included, the “angioplasty market” would be much larger (driven by the enormous coronary stent market). For our purposes, CAD-related sales are largely outside “peripheral angioplasty.” Nonetheless, some device platforms (e.g. angioplasty balloons, catheters) are used in both coronary and peripheral realms, and companies often cross-leverage R&D.
- Others (Renal, Carotid, etc.): A small portion of angioplasty devices go into other vascular beds. Renal artery angioplasty (for renal stenosis) and carotid angioplasty (for stroke prevention) use similar balloon/stent products and appear in adjacent markets (renal angioplasty devices, carotid stents). These applications typically account for only a minor share (<10%) of the peripheral angioplasty market. However, “other” segments exist and allow device makers to diversify.
By End User
- Hospitals (Catheterization Labs): The largest share of angioplasty procedures is performed in hospital interventional suites. Hospitals have the full imaging and surgical backup needed for complex PAD cases. According to MRFR, hospitals generated “the most income” in peripheral angioplasty. They also facilitate emergency interventions for acute limb ischemia.
- Ambulatory Surgical Centers (ASCs) and Specialty Clinics: A growing share of PAD interventions is migrating to outpatient settings. In many markets, specialized vascular clinics or ASCs handle non-complex angioplasties. These centers benefit from lower overhead and allow …